C Eick1, M Duckheim1, P Groga-Bada1, N Klumpp1, S Mannes1, C S Zuern1, M Gawaz1, K D Rizas2,3, Axel Bauer4,5. 1. Medizinische Klinik III, Eberhard-Karls-Universität Tübingen, Tübingen, Germany. 2. Medizinische Klinik und Poliklinik I, Munich University Clinic, Marchioninistr. 15, 81377, Munich, Germany. 3. German Center for Cardiovascular Research (DZHK), Munich, Germany. 4. Medizinische Klinik und Poliklinik I, Munich University Clinic, Marchioninistr. 15, 81377, Munich, Germany. axel.bauer@med.uni-muenchen.de. 5. German Center for Cardiovascular Research (DZHK), Munich, Germany. axel.bauer@med.uni-muenchen.de.
Abstract
BACKGROUND: Impaired cardiac autonomic function has been linked to adverse outcomes in patients with acute coronary syndromes (ACS) but is not included in clinical risk models. This is the first study to investigate whether point-of-care testing of cardiac autonomic function by means of short-term deceleration capacity (DC) of heart rate improves risk assessment in patients with suspected ACS. METHODS: 1821 patients with suspected ACS were prospectively enrolled if they were older than 17 years and in sinus rhythm. Short-term DC was automatically assessed from monitor recordings at hospital admission. The Global Registry of Acute Coronary Events (GRACE) score was used as gold standard risk predictor. Primary endpoint was the composite of intrahospital and 30-day mortality. Secondary endpoint was 180-day mortality. RESULTS: Of the 1,821 patients with suspected ACS, 28 (1.5%) and 60 (3.3%) reached the primary and secondary endpoints, respectively. DC was a highly significant predictor of both endpoints, yielding areas under the curve (AUC) of 0.784 (95% CI 0.714-0.854) and 0.781 (0.727-0.832) (p < 0.001 for both), respectively. Implementing DC into the GRACE-risk model leads to a significant increase of the C-statistics from 0.788 (0.703-0.874) to 0.825 (0.750-0.900; p < 0.01 for difference) and from 0.814 (0.759-0.864) to 0.851 (0.808-0.889; p < 0.01 for difference) for the primary and secondary endpoints, respectively. Stratification by dichotomized DC was especially powerful in patients with GRACE score <140. CONCLUSIONS: In patients with suspected ACS, point-of-care testing of cardiac autonomic function by means of DC is feasible and improves risk assessment by the GRACE score. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov NCT01486589.
BACKGROUND: Impaired cardiac autonomic function has been linked to adverse outcomes in patients with acute coronary syndromes (ACS) but is not included in clinical risk models. This is the first study to investigate whether point-of-care testing of cardiac autonomic function by means of short-term deceleration capacity (DC) of heart rate improves risk assessment in patients with suspected ACS. METHODS: 1821 patients with suspected ACS were prospectively enrolled if they were older than 17 years and in sinus rhythm. Short-term DC was automatically assessed from monitor recordings at hospital admission. The Global Registry of Acute Coronary Events (GRACE) score was used as gold standard risk predictor. Primary endpoint was the composite of intrahospital and 30-day mortality. Secondary endpoint was 180-day mortality. RESULTS: Of the 1,821 patients with suspected ACS, 28 (1.5%) and 60 (3.3%) reached the primary and secondary endpoints, respectively. DC was a highly significant predictor of both endpoints, yielding areas under the curve (AUC) of 0.784 (95% CI 0.714-0.854) and 0.781 (0.727-0.832) (p < 0.001 for both), respectively. Implementing DC into the GRACE-risk model leads to a significant increase of the C-statistics from 0.788 (0.703-0.874) to 0.825 (0.750-0.900; p < 0.01 for difference) and from 0.814 (0.759-0.864) to 0.851 (0.808-0.889; p < 0.01 for difference) for the primary and secondary endpoints, respectively. Stratification by dichotomized DC was especially powerful in patients with GRACE score <140. CONCLUSIONS: In patients with suspected ACS, point-of-care testing of cardiac autonomic function by means of DC is feasible and improves risk assessment by the GRACE score. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov NCT01486589.
Authors: Petra Hillinger; Raphael Twerenbold; Karin Wildi; Maria Rubini Gimenez; Cedric Jaeger; Jasper Boeddinghaus; Thomas Nestelberger; Karin Grimm; Tobias Reichlin; Fabio Stallone; Christian Puelacher; Zaid Sabti; Nikola Kozhuharov; Ursina Honegger; Paola Ballarino; Oscar Miro; Kris Denhaerynck; Temizel Ekrem; Claudia Kohler; Roland Bingisser; Stefan Osswald; Christian Mueller Journal: Clin Res Cardiol Date: 2016-07-12 Impact factor: 5.460
Authors: Christian Eick; Konstantinos D Rizas; Christine S Meyer-Zürn; Patrick Groga-Bada; Wolfgang Hamm; Florian Kreth; Dietrich Overkamp; Peter Weyrich; Meinrad Gawaz; Axel Bauer Journal: Crit Care Med Date: 2015-05 Impact factor: 7.598
Authors: Philippe Gabriel Steg; Robert J Goldberg; Joel M Gore; Keith A A Fox; Kim A Eagle; Marcus D Flather; Immad Sadiq; Rachel Kasper; Sophie K Rushton-Mellor; Frederick A Anderson Journal: Am J Cardiol Date: 2002-08-15 Impact factor: 2.778
Authors: Axel Bauer; Petra Barthel; Raphael Schneider; Kurt Ulm; Alexander Müller; Anke Joeinig; Raphael Stich; Antti Kiviniemi; Katerina Hnatkova; Heikki Huikuri; Albert Schömig; Marek Malik; Georg Schmidt Journal: Eur Heart J Date: 2008-12-23 Impact factor: 29.983
Authors: Rasmus Rivinius; Matthias Helmschrott; Arjang Ruhparwar; Ann-Kathrin Rahm; Fabrice F Darche; Dierk Thomas; Tom Bruckner; Philipp Ehlermann; Hugo A Katus; Andreas O Doesch Journal: Clin Res Cardiol Date: 2017-11-02 Impact factor: 5.460